Feeling genuinely grateful to the @sunydownstate biotechnology incubator in Brooklyn for hosting our @EpiOneInc team in such a supportive environment for serious science and a real sense of purpose. We are lucky to be here.

Innovation in #cancercare matters, but it’s only part of the equation. We spoke with leaders from @SiemensHealth, @PennCancer, and @EpiOneInc to uncover where startups should focus and why the path forward demands more than technology alone. Read it:

Feeling excited about what this year holds for @EpiOneInc — important steps ahead, and work that really matters. Grateful for the team. Onward.

Quiet progress, steady momentum. We’re expanding our clinical validation efforts for early cancer detection — working with top academic centers and scaling our lab capacity. More to come. But for now: forward. #CancerDetection #PrecisionDiagnostics #EpiOne

17 years. That’s how long I’ve kept up my streak of running at least 3 miles every single day — through rain, jet lag, illness, and more than a few 3:30am alarms. Reminds me a lot of building a startup: discipline matters more than inspiration, consistency more than bursts of

A detailed look at the role of AI in cancer detection >> Artificial intelligence may mitigate overdiagnosis and unnecessary treatments in cancer care by integrating with precision medicine.

A new blood test promising near-perfect accuracy is reshaping the future of testicular cancer detection—and high-profile voices are calling it a game-changer

A new study has found that fragments of tumor DNA in a patient's bloodstream could show that they are at high risk of a melanoma recurrence. https://t.co/mHqz0U2KAS

Congratulations to British HealthTech company @SkinAnalytics, which has raises €17 million to deliver AI skin cancer detection https://t.co/p19HYsF0LQ

Talking on the fantastic Passion Struck podcast, our CEO @marquardtglobal outlines how we at Epi One firmly believe that we're at a turning point in the battle against cancer...

"Without scientist Kseniia Petrova’s expertise, no one can fully unlock the data’s potential, putting crucial advancements in early cancer detection at risk", says @nbcnews

Researchers from the Faculty of Physics and the Life Sciences Center of Vilnius University, with co-authors from other organisations, have developed a method that can improve the diagnostics of cancer and other diseases using laser light.

Michael Marquardt and Sophia F. Fang, MD, PhD were recently shown around potential new laboratory space in Delaware as we look to expand our operations.

A clinical trial co-led by Yale Urology shows that high resolution micro-ultrasound is an effective tool for guiding prostate cancer biopsies.

A tiny robot that can take 3D scans from deep within the body has been developed by engineers at the University of Leeds in the UK, potentially revolutionising the early detection of cancer. https://t.co/DFr4r7Bfst

The recent All In Against Cancer campaign saw our CEO Michael Marquardt join a large group of esteemed experts in the cancer space to brainstorm ideas on how to end cancer as we know it.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat, the first prostate-specific membrane antigen-targeting product authorised for use with technetium-99m to detect cancerous lesions in men with prostate cancer.

Some great progress from VolitionRx, which has announced that its Nu.Q cancer immunoassay test was able to detect at least 21 different cancers in a recent study. The research also showed that the test has a low false-positive rate.

Researchers from around the U.K., led by the University of Oxford, have found that a new way of performing prostate biopsies is better at diagnosing prostate cancer, but takes longer to perform and is more painful for patients.

At the @americancancer summit in Florida, our CEO @marquardtglobal joined an esteemed group of cancer experts to brainstorm ideas around how to end cancer as we know it.